Home » ADVENTRX PRESENTS RESPONSE DATA FOR ENROLLMENT IN CANCER TRIAL
ADVENTRX PRESENTS RESPONSE DATA FOR ENROLLMENT IN CANCER TRIAL
Adventrx Pharmaceuticals has announced response data from all 48 measurable patients in its 50-patient Phase II trial with CoFactor and 5-fluorouracil (5-FU) as a first-line treatment for metastatic colorectal cancer.
CoFactor is Adventrx's biomodulator designed to enhance the effects of the widely used cancer drug, 5-FU. A poster of these results was presented at the 7th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Sixty-five percent, or 31 patients, treated with CoFactor and 5-FU achieved clinical benefit, defined as tumor response or stable disease following study therapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct